Neuromodulation and Language Acquisition (Stage Ib)
The purpose of this study is to determine whether rivastigmine or pramipexol are effective in boosting semantic language acquisition in healthy subjects.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Neuromodulation and Language Acquisition (KS-Neuromod_01, Stage Ib)|
- Boost in language learning success (percent hits) through neuromodulation
- Stability of language learning success after one week, one month, and one year
|Study Start Date:||January 2005|
|Estimated Study Completion Date:||June 2006|
Our prior work shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind clinical trial, we probe whether a selective d2/d3 dopamine agonist (pramipexole) or cholinergic neuromodulation (rivastigmine), after a titration period of five days, will yield a learning enhancement comparable to using levodopa in healthy subjects. The expected scientific results will strengthen the basis for transferring neuromodulatory interventions from the laboratory to stroke patients with language dysfunctions.
|Dept. of Neurology, University Hospital Muenster|
|Muenster, Nordrhein-Westfalen, Germany, 48129|
|Study Director:||Caterina Breitenstein, PhD||Dept. of Neurology, University Hospital Muenster|
|Study Chair:||Stefan Knecht, MD||Dept. of Neurology, University Hospital Muenster|